Senti Biosciences, Inc. Appoints Kanya Rajangam as Chief Medical and Development Officer
Kanya Rajangam, MD, Ph.D., has been named Chief Medical and Development Officer at Senti Biosciences, Inc. Dr. Rajangam, who will join the company in July, is a seasoned biotechnology executive with a proven track record of developing cancer therapies across multiple modality platforms. Dr. Rajangam will be broadly responsible for leading the development and regulatory strategy to rapidly advance Senti Bio’s off-the-shelf CAR-NK cell oncology programs into and through clinical development as Chief Medical and Development Officer.
Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with “gene circuits.
Senti Biosciences’s estimated annual revenue is currently $17.4M per year.